company background image
VERU

VeruNasdaqCM:VERU Stock Report

Market Cap

US$707.5m

7D

1.7%

1Y

242.1%

Updated

28 Sep, 2021

Data

Company Financials +
VERU fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

VERU Overview

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers.

Veru Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Veru
Historical stock prices
Current Share PriceUS$8.86
52 Week HighUS$2.30
52 Week LowUS$24.57
Beta0.62
1 Month Change-2.53%
3 Month Change9.79%
1 Year Change242.09%
3 Year Change568.68%
5 Year Change650.85%
Change since IPO33.74%

Recent News & Updates

Shareholder Returns

VERUUS Personal ProductsUS Market
7D1.7%2.6%2.0%
1Y242.1%48.0%32.8%

Return vs Industry: VERU exceeded the US Personal Products industry which returned 48% over the past year.

Return vs Market: VERU exceeded the US Market which returned 32.8% over the past year.

Price Volatility

Is VERU's price volatile compared to industry and market?
VERU volatility
VERU Beta0.62
Industry Beta1.04
Market Beta1

Stable Share Price: VERU is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: VERU's weekly volatility has decreased from 17% to 8% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1971339Mitch Steinerhttps://www.verupharma.com

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include VERU-111, an oral chemical entity that is being evaluated in open label Phase 1b and Phase 2 clinical trials in men with metastatic castration and androgen receptor targeting agent resistant prostate cancer, as well as being evaluated in a Phase 2 clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome; and for the treatment of taxane resistant metastatic triple negative breast cancer.

Veru Fundamentals Summary

How do Veru's earnings and revenue compare to its market cap?
VERU fundamental statistics
Market CapUS$707.50m
Earnings (TTM)-US$143.69k
Revenue (TTM)US$57.36m

12.3x

P/S Ratio

-4.9kx

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VERU income statement (TTM)
RevenueUS$57.36m
Cost of RevenueUS$12.18m
Gross ProfitUS$45.18m
ExpensesUS$45.32m
Earnings-US$143.69k

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0018
Gross Margin78.76%
Net Profit Margin-0.25%
Debt/Equity Ratio7.5%

How did VERU perform over the long term?

See historical performance and comparison

Valuation

Is Veru undervalued compared to its fair value and its price relative to the market?

4.57x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: VERU ($8.86) is trading above our estimate of fair value ($0.53)

Significantly Below Fair Value: VERU is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: VERU is unprofitable, so we can't compare its PE Ratio to the US Personal Products industry average.

PE vs Market: VERU is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VERU's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: VERU is overvalued based on its PB Ratio (4.6x) compared to the US Personal Products industry average (2.8x).


Future Growth

How is Veru forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

63.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VERU is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VERU is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VERU is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VERU's revenue (40.7% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: VERU's revenue (40.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if VERU's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Veru performed over the past 5 years?

-6.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VERU is currently unprofitable.

Growing Profit Margin: VERU is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: VERU is unprofitable, and losses have increased over the past 5 years at a rate of 6.6% per year.

Accelerating Growth: Unable to compare VERU's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VERU is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (54.7%).


Return on Equity

High ROE: VERU has a negative Return on Equity (-0.092%), as it is currently unprofitable.


Financial Health

How is Veru's financial position?


Financial Position Analysis

Short Term Liabilities: VERU's short term assets ($154.4M) exceed its short term liabilities ($17.2M).

Long Term Liabilities: VERU's short term assets ($154.4M) exceed its long term liabilities ($7.9M).


Debt to Equity History and Analysis

Debt Level: VERU's debt to equity ratio (7.5%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if VERU's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VERU has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if VERU has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Veru current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VERU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VERU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VERU's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VERU's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: VERU is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VERU's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.4yrs

Average management tenure


CEO

Mitch Steiner (60 yo)

4.92yrs

Tenure

US$1,263,303

Compensation

Dr. Mitchell S. Steiner, also known as Mitch, M.D., F.A.C.S, has been the Chief Executive Officer, President and Director at Veru Inc. (formerly known as The Female Health Company) since October 31, 2016 &...


CEO Compensation Analysis

Compensation vs Market: Mitch's total compensation ($USD1.26M) is below average for companies of similar size in the US market ($USD2.28M).

Compensation vs Earnings: Mitch's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: VERU's management team is considered experienced (3.4 years average tenure).


Board Members

Experienced Board: VERU's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: VERU insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.3%.


Top Shareholders

Company Information

Veru Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Veru Inc.
  • Ticker: VERU
  • Exchange: NasdaqCM
  • Founded: 1971
  • Industry: Personal Products
  • Sector: Household
  • Market Cap: US$707.504m
  • Shares outstanding: 79.85m
  • Website: https://www.verupharma.com

Number of Employees


Location

  • Veru Inc.
  • 48 NW 25th Street
  • Suite 102
  • Miami
  • Florida
  • 33127
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/28 22:29
End of Day Share Price2021/09/28 00:00
Earnings2021/06/30
Annual Earnings2020/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.